Jianhao Xu1, Liwei Ni2, Fenglun Zhao3, Xiaoxiao Dai4, Jialong Tao5, Jia Pan3, Aiming Shi3, Zhu Shen3, Cunjin Su3, Yusong Zhang5. 1. Department of Pathology, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan 215300, Jiangsu, PR China. 2. Department of Medical Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, Zhejiang, PR China. 3. Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu, PR China. 4. Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu, PR China. 5. Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu, PR China.
Abstract
BACKGROUND: This study aimed to investigate the aberrant expression of hsa_circ_0002874 in non-small cell lung cancer (NSCLC) and elucidate associated molecular mechanisms that influence apoptosis and induce paclitaxel (PTX) resistance. METHODS: Inhibitors were used to downregulate circRNA or miRNA expression. pCDNA plasmid transfection and mimics were used to upregulate circRNA or miRNA expression. Dual-luciferase reporter assays were conducted to evaluate interactions between miR1273f and MDM2. Xenograft tumor models were used to assess the effect of hsa_circ_0002874 and miR1273f on tumor growth. NSCLC tissues and matched non-cancerous tissues were also collected for correlation analysis. RESULTS: hsa_circ_0002874 acts as a sponge for miR1273f which targets MDM2/P53. The stability of the hsa_circ_0002874/miR1273f/MDM2/P53 pathway was verified by upregulating and downregulating the expression of hsa_circ_0002874 and miR1273f. hsa_circ_0002874 downregulation or miR1273f upregulation reversed the resistance of the A549/Taxol cells in xenograft models. The expression of hsa_circ_0002874 was high, and the level of MDM2 was low in NSCLC tissues. P53 was only weakly expressed in NSCLC tissues with high expression of MDM2. CONCLUSIONS: hsa_circ_0002874 is strongly expressed in NSCLC tissues and maybe a potential marker for PTX resistance. hsa_circ_0002874 downregulation could regulate miR1273f/MDM2/P53 signaling pathway to reverse the PTX resistance of NSCLC and induce apoptosis in vitro and vivo.
BACKGROUND: This study aimed to investigate the aberrant expression of hsa_circ_0002874 in non-small cell lung cancer (NSCLC) and elucidate associated molecular mechanisms that influence apoptosis and induce paclitaxel (PTX) resistance. METHODS: Inhibitors were used to downregulate circRNA or miRNA expression. pCDNA plasmid transfection and mimics were used to upregulate circRNA or miRNA expression. Dual-luciferase reporter assays were conducted to evaluate interactions between miR1273f and MDM2. Xenograft tumor models were used to assess the effect of hsa_circ_0002874 and miR1273f on tumor growth. NSCLC tissues and matched non-cancerous tissues were also collected for correlation analysis. RESULTS: hsa_circ_0002874 acts as a sponge for miR1273f which targets MDM2/P53. The stability of the hsa_circ_0002874/miR1273f/MDM2/P53 pathway was verified by upregulating and downregulating the expression of hsa_circ_0002874 and miR1273f. hsa_circ_0002874 downregulation or miR1273f upregulation reversed the resistance of the A549/Taxol cells in xenograft models. The expression of hsa_circ_0002874 was high, and the level of MDM2 was low in NSCLC tissues. P53 was only weakly expressed in NSCLC tissues with high expression of MDM2. CONCLUSIONS: hsa_circ_0002874 is strongly expressed in NSCLC tissues and maybe a potential marker for PTX resistance. hsa_circ_0002874 downregulation could regulate miR1273f/MDM2/P53 signaling pathway to reverse the PTX resistance of NSCLC and induce apoptosis in vitro and vivo.
Authors: Tao Wang; Xiaoxu Wang; Qianyu Du; Nan Wu; Xincheng Liu; Yuqing Chen; Xiaojing Wang Journal: Biochem Biophys Res Commun Date: 2019-04-17 Impact factor: 3.575
Authors: Syed S Razi; Sadiq Rehmani; Xiaogui Li; Koji Park; Gary S Schwartz; Mohammed J Latif; Faiz Y Bhora Journal: J Surg Res Date: 2014-11-10 Impact factor: 2.192
Authors: J E Kravchenko; G V Ilyinskaya; P G Komarov; L S Agapova; D V Kochetkov; E Strom; E I Frolova; I Kovriga; A V Gudkov; E Feinstein; P M Chumakov Journal: Proc Natl Acad Sci U S A Date: 2008-04-18 Impact factor: 11.205
Authors: Julio Sánchez de Cos; M Agustín Sojo González; María Victoria Montero; María Cristina Pérez Calvo; María Jesús Martín Vicente; Manuel Hernández Valle Journal: Lung Cancer Date: 2008-06-16 Impact factor: 5.705
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Ya Pan; Wenjuan Chen; Xiangyun Yan; Boshi Yu; Shuwen Yao; Xiaohui Chen; Shuping Han Journal: Biomed Res Int Date: 2021-11-03 Impact factor: 3.411